^
Association details:
| Biomarker: | CCR2 overexpression |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug: | TAK-500 (STING agonist, CCR2-targeted antibody-drug conjugate) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Abstract 1841: TAK-500 is a clinical stage immune-cell directed antibody drug conjugate (iADC) inducing STING activation in CCR2-expressing intratumor myeloid cells and favorable immunomodulation
Published date:
04/04/2023
Excerpt:
The iADC TAK-500 and mTAK-500 induces CCR2-dependent immune cell activation and anti-tumor effect. CCR2 is highly expressed in intratumor myeloid cells from NSCLC. High CCR2 is associated with enhanced local adaptive immune responses and specific clinical/molecular tumor subsets.
DOI:
10.1158/1538-7445.AM2023-1841
